Biotechnology Value Fund — 2020 Investments
3 investments dated 2020 · listed companies and verified rows first · show all
4DMT is a late-stage biotechnology company that develops gene delivery systems and genetic therapeutics targeting specific tissue types for various diseases.
BiotechHealthtechEmeryville, US
David Kirn(Chief Executive Officer, President, and Co-Founder)inDavid Schaffer(Director)inTheresa Janke(Chief of Staff, Co-Founder)in
BoardSharon Tetlow(Director)Margi McLoughlin(Director)
Co-investorsAmzak HealthBerkeley CatalystBOLD LongevityCasdin CapitalChiesi VenturesHercules Capital, Inc.+8 more
Dren Bio is a clinical-stage biopharmaceutical company developing novel antibody therapeutics designed to selectively eliminate pathogenic cells and disease-causing agents, with a pipeline targeting oncology, autoimmune diseases, immunology, and neurology.
BiotechHealthtechMedical DevicesFoster City, US
Nenad Tomasevic(Founder)
BoardIvan Trifunovich(Director)John Wesley(Founder)
Co-investors8VCAisling CapitalHBM Healthcare InvestmentsHBM PartnersJacket River Capital PartnersMission Bay Capital+5 more
BiotechFremont, US
Avanish Vellanki(Executive Officer)in
Co-investorsJanus Henderson InvestorsSamsara BioCapital
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.










